Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.
Sanjay Popat, BSc, MBBS, FRCP, PhD
Advertisement
Articles by Sanjay Popat, BSc, MBBS, FRCP, PhD
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
The OncFive: Top Oncology Articles for the Week of 7/12
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5